Compliance certificate under Reg 74(5) of SEBI (DP) Regulations
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Parmax Pharma Ltd has submitted a routine compliance certificate to BSE for the quarter ended June 30, 2025, along with confirmation from its Registrar and Share Transfer Agent (RTA), Purva Sharegistry (India) Pvt. Ltd. The certificate confirms that all share certificates received for dematerialization during the quarter were properly verified, mutilated, cancelled, and the depository's name was recorded as the registered owner within the timelines required by SEBI regulations. The filing also confirms that the dematerialized securities continue to be listed on the stock exchange where the company's shares are already listed. The document is signed by Umang Gosalia, Managing Director of the company, and Ms. Deepali Dhuri, Compliance Officer of the RTA.
This is a standard procedural regulatory filing required every quarter and carries no material business or financial information. It has no direct impact on shareholders or the stock price — it merely confirms routine housekeeping of share dematerialization records is in order.